Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History COCP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics COCP

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Cocrystal Pharma Inc

COCP
Current price
1.67 USD -0.05 USD (-2.91%)
Last closed 1.70 USD
ISIN US19188J4094
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 16 075 231 USD
Yield for 12 month -28.94 %
1Y
3Y
5Y
10Y
15Y
COCP
21.11.2021 - 28.11.2021

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. It employs structure-based technologies to create antiviral drugs including influenza virus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as norovirus, respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhibitor, which is in phase 2a clinical trial, as a potential treatment for pandemic and seasonal influenza A; and the inhaled CC-42344 for the potential prophylactic treatment of pandemic and seasonal influenza infections. It is also developing CDI-988, an oral pan-viral, which is phase 1 clinical trial to treat noroviruses and coronaviruses, including SARS-CoV-2 and its variants; and CC-31244, a HCV non-nucleoside inhibitor that has completed Phase 2a clinical trial to treat HCV. The company has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; and a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections. Cocrystal Pharma, Inc. was founded in 2006 and is based in Bothell, Washington. Address: 19805 North Creek Parkway, Bothell, WA, United States, 98011

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

8.00 USD

P/E Ratio

Dividend Yield

Financials COCP

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures COCP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

-15 169 000 USD

Current Quarter

Last Quarter

EBITDA -15 945 000 USD
Operating Margin TTM
Price to Earnings
Return On Assets TTM -53.96 %
PEG Ratio
Return On Equity TTM -106.05 %
Wall Street Target Price 8.00 USD
Revenue TTM 510 000 USD
Book Value 0.72 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 26.90 %
Dividend Yield
Gross Profit TTM -10 947 000 USD
Earnings per share -1.56 USD
Diluted Eps TTM -1.56 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation COCP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 17.89
Price Sales TTM 92.45
Enterprise Value EBITDA 0.66
Price Book MRQ 2.17

Technical Indicators COCP

For 52 Weeks

1.12 USD 3.26 USD
50 Day MA 1.54 USD
Shares Short Prior Month 4 760
200 Day MA 1.78 USD
Short Ratio 0.18
Shares Short 4 470
Short Percent 0.060 %